AstraZeneca | 6-K: Enhertu Approved in the US as First Tumour-agnostic HER2-directed Therapy for Previously Treated Patients with Metastatic HER2-positive solid Tumours
AstraZeneca | 6-K: Enhertu Approved in the US as First Tumour-agnostic HER2-directed Therapy for Previously Treated Patients with Metastatic HER2-positive solid Tumours
阿斯利康 | 6-K：Enhertu在美國獲准成爲首款針對先前接受過轉移性HER2陽性實體瘤治療患者的與腫瘤無關的HER2導向療法
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。